Cargando…

Factors influencing adherence to non-vitamin K antagonist oral anticoagulants in the early period after atrial fibrillation catheter ablation in China

Supplemental Digital Content is available in the text

Detalles Bibliográficos
Autores principales:	Hu, Zhi-Cheng, Liu, Shang-Yu, Wu, Ling-Min, Shen, Li-Shui, Liu, Li-Min, Li, Guo-Liang, Zheng, Li-Hui, Yao, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Clinical Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462210/ https://www.ncbi.nlm.nih.gov/pubmed/32826466 http://dx.doi.org/10.1097/CM9.0000000000001000

Ejemplares similares

Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation
por: Yamaji, Hirosuke, et al.
Publicado: (2017)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment
por: Zhang, Rong-feng, et al.
Publicado: (2021)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
por: Vamos, Mate, et al.
Publicado: (2016)

Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation
por: van Vugt, Stijn P G, et al.
Publicado: (2021)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
por: Murakawa, Yuji, et al.
Publicado: (2017)

Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation
por: De Heide, John, et al.
Publicado: (2018)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Utilization of Anticoagulants in Nonvalvular Atrial Fibrillation Before and After Catheter Ablation at Shanghai, China
por: Tingting, Chen, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants
por: Yamaji, Hirosuke, et al.
Publicado: (2016)

Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation
por: Gjermeni, Diona, et al.
Publicado: (2023)

Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
por: Tang, Lihong, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants
por: Brinkmeier-Theofanopoulou, Maria, et al.
Publicado: (2018)

Uninterrupted or Minimally Interrupted Direct Oral Anticoagulant Therapy is a Safe Alternative to Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Meta-Analysis
por: Ottóffy, Máté, et al.
Publicado: (2020)

Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2015)

Catheter Ablation for Atrial Fibrillation
por: Gauri, Andre J, et al.
Publicado: (2003)

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
por: Wu, Victor Chien-Chia, et al.
Publicado: (2023)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
por: Komen, Joris J, et al.
Publicado: (2021)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis
por: Xiong, Qinmei, et al.
Publicado: (2019)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
por: Kim, Kyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3dbu5vj15ng59megmjuc4hp42v